<DOC>
	<DOCNO>NCT02040935</DOCNO>
	<brief_summary>This single-arm , open-label , local multicenter study evaluate safety tolerability Herceptin ( trastuzumab ) administer subcutaneously single-use injection device ( SID ) patient HER2-positive early breast cancer . Following surgery ( neo-adjuvant adjuvant chemotherapy ) , patient receive Herceptin 600 mg subcutaneously SID every 3 week total 1 year , unless disease recurrence unacceptable toxicity occurs . After first 3 cycle , patient permit self-administer Herceptin supervision HCP .</brief_summary>
	<brief_title>A Study Subcutaneous Herceptin ( Trastuzumab ) Administered Home By Single-Use Injection Device Patients With Early HER2-Positive Breast Cancer ( HOMERUS )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Female male patient , &gt; /= 18 year age Histologically confirm nonmetastatic primary invasive adenocarcinoma breast HER2positive disease Eastern Cooperative Oncology Group ( ECOG ) performance status 01 Hormonal therapy allow per institutional guideline Prior use antiHER2 therapy allow except early breast cancer patient neoadjuvant set Left ventricular ejection fraction &gt; /= 55 % No evidence residual , locally recurrent metastatic disease completion surgery chemotherapy , concurrent chemotherapy ( neoadjuvant adjuvant ) Use concurrent radiotherapy permit Completion surgery chemotherapy ( applicable ) early breast cancer History malignancy , except patient curatively treat carcinoma situ cervix basal cell carcinoma patient curatively treated malignancy diseasefree last 5 year Patients severe dyspnea rest require supplementary oxygen therapy Patients concurrent serious disease might interfere plan treatment , include severe pulmonary conditions/illness Serious cardiac illness medical condition would preclude use trastuzumab , specifically : history document congestive heart failure , highrisk uncontrolled arrhythmia , angina pectoris require medication , clinically significant valvular disease , evidence transmural infarction ECG , poorly control hypertension Pregnant lactate woman Women childbearing potential male patient female partner childbearing potential unable unwilling use adequate contraceptive method study treatment Concurrent enrolment another clinical trial use investigational anticancer treatment , include hormonal therapy , biphosphonate therapy immunotherapy , within 28 day prior first dose study treatment Known hypersensitivity trastuzumab , murine protein , excipients Herceptin include hyaluronidase , adhesive SC device , history severe allergic immunological reaction , e.g . difficult control asthma Inadequate bone marrow , hepatic renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>